Skip to main content Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: LYEL

Lyell Immunopharma, Inc.

Healthcare | Biotechnology
$15.76 as of 2026-09-05 01:02 UTC
Market Cap$390M
Volume169.7K
EPS (TTM)$-16.06

Lyell Immunopharma, Inc. (NASDAQ: LYEL) is a $390M biotechnology company trading at $15.76. Figures from SEC EDGAR and market feeds; updated 2026-09-05 01:02 UTC.

What Lyell Immunopharma, Inc. does

Lyell Therapeutics is a clinical-stage cell therapy company developing autologous chimeric antigen receptor T-cell products to treat cancer. The company's lead program, rondecabtagene autoleucel (ronde-cel), is a dual-targeting CAR T-cell therapy designed to improve outcomes in large B-cell lymphoma by targeting B cells through two pathways and generating more durable immune cells. Ronde-cel is being evaluated in two clinical trials: a pivotal single-arm study in heavily pretreated patients and a Phase 3 head-to-head randomized trial against approved CAR T therapies.

Summarized from Lyell Immunopharma, Inc.’s SEC filings · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Quote
Price$15.76
Market cap$390M
Volume169.7K shares
Valuation
EPS (TTM)$-16.06
Price/book1.57×

Revenue, margins & earnings

FY2021: net loss $250M on revenue $11M$11MFY2021FY2022: net loss $183M on revenue $85M$85MFY2022FY2023: net loss $235M on revenue $130,000$130,000FY2023FY2024: net loss $343M on revenue $61,000$61,000FY2024FY2025: net loss $274M on revenue $36,000$36,000FY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-08-25
  • 2026-08-25Hill Stephen J.Chief Operating OfficerSELL-989$15.4K
  • 2026-08-25Seely LynnPresident and CEOSELL-9,589$149.0K
  • 2026-08-25Lee Gary K.Chief Scientific OfficerSELL-1,457$22.6K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Lyell Immunopharma, Inc. do?

Lyell Therapeutics is a clinical-stage cell therapy company developing autologous chimeric antigen receptor T-cell products to treat cancer.

What is LYEL's valuation?

LYEL trades at $15.76, as of 2026-09-05.

When did LYEL last file with the SEC?

Lyell Immunopharma, Inc.'s most recent SEC filing on record is a 10-Q filed 2026-08-06. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings and public market data feeds, fetched 2026-09-05 01:02 UTC. This page is also available as JSON at /api/data?ticker=LYEL and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for LYEL and 5,000+ tickers.

Create a free account — keep LYEL
For your agent
GET /api/data?ticker=LYEL

This page as JSON via rel="alternate" · REST API docs · MCP server (59 tools) · llms.txt